Press Release Service: RoslinCT and Ayrmid Ltd. Announce Expansion of Strategic Partnership to Manufacture Omisirge® (omidubicel-onlv) for Second FDA-Approved Indication in Severe Aplastic Anemia (SAA) - CRISPR Medicine
Technology Transfer News
RoslinCT is performing technology transfer and will support commercial manufacture of Omisirge® for an additional indication following successful ...
